# A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

> **NCT02620020** · PHASE2,PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 563 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** Fasinumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02620020
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2017-02-03
- **Final completion:** 2017-09-13
- **Target enrollment:** 563 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620020, "A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02620020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*